![]() Bococizumab structure
|
Common Name | Bococizumab | ||
---|---|---|---|---|
CAS Number | 1407495-02-6 | Molecular Weight | N/A | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | N/A | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of BococizumabBococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia[1][2]. |
Name | Bococizumab |
---|
Description | Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia[1][2]. |
---|---|
Related Catalog | |
Target |
PCSK9[1] |
In Vivo | Bococizumab (0-100 mg/kg, i.v.) decreases maternal and fetal cholesterol and does not affect rat embryo-fetal development[2]. Animal Model: Pregnant Sprague-Dawley (SD) rats[1] Dosage: 0, 10, 30, and 100 mg/kg Administration: Intravenous injection (i.v.) Result: Decreased in fetal cholesterol levels. Showed well tolerance and no effects on ovarian or uterine parameters. |
References |
No Any Chemical & Physical Properties |